CA2373486A1 - Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine - Google Patents

Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine Download PDF

Info

Publication number
CA2373486A1
CA2373486A1 CA002373486A CA2373486A CA2373486A1 CA 2373486 A1 CA2373486 A1 CA 2373486A1 CA 002373486 A CA002373486 A CA 002373486A CA 2373486 A CA2373486 A CA 2373486A CA 2373486 A1 CA2373486 A1 CA 2373486A1
Authority
CA
Canada
Prior art keywords
phage
enterococcus faecium
vancomycin
pta
enb6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373486A
Other languages
English (en)
Inventor
Carl R. Merril
Richard M. Carlton
Sankar Adhya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Exponential Biotherapies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2373486A1 publication Critical patent/CA2373486A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

la présente invention concerne l'utilisation de bactériophages spécifiques, appelés ENB6 et ENB13, qui tuent nombre d'isolats cliniques de Enterococcus faecium résistant à la vancomycine et de Enterococcus faecium sensible à la vancomycine. Le génome d'une des souches de ces bactériophages, ENB6 à été partiellement séquencé, et il apparaît qu'il ne contient pas de séquences nucléotidiques correspondant à des gènes à virulence bactérienne connus et à une cassette présentant une résistance à la vancomycine. Son efficacité qui a permis de sauver des souris de bactériémie dont l'issue aurait en d'autres circonstances été fatale, est présentée dans ce dossier.
CA002373486A 1999-05-13 2000-05-12 Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine Abandoned CA2373486A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13405599P 1999-05-13 1999-05-13
US60/134,055 1999-05-13
PCT/US2000/006718 WO2000069269A1 (fr) 1999-05-13 2000-05-12 Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine

Publications (1)

Publication Number Publication Date
CA2373486A1 true CA2373486A1 (fr) 2000-11-23

Family

ID=22461568

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373486A Abandoned CA2373486A1 (fr) 1999-05-13 2000-05-12 Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine

Country Status (5)

Country Link
EP (1) EP1180937A4 (fr)
JP (1) JP2002543816A (fr)
AU (1) AU4971900A (fr)
CA (1) CA2373486A1 (fr)
WO (1) WO2000069269A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250143A2 (fr) 2000-01-11 2002-10-23 Intralytix Inc. Reduction de la colonisation bacterienne par administration de compositions bacteriophages
US6759229B2 (en) 2001-12-18 2004-07-06 President & Fellows Of Harvard College Toxin-phage bacteriocide antibiotic and uses thereof
GB0209680D0 (en) * 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
WO2004052274A2 (fr) 2002-12-09 2004-06-24 Phage Biopharm Llc Production de compositions bacteriophages destinees a etre utilisees dans la therapie phagique
DE10342071B4 (de) * 2003-09-10 2006-01-19 Fleischmann, Wilhelm, Dr.med. Vorrichtung und Verfahren zur Applikation von Wïrkstoffen an eine Wundoberfläche
US8178087B2 (en) 2006-04-04 2012-05-15 Centre National de la Recherche Scientifique —CNRS Process of production of bacteriophage compositions and methods in phage therapy field
KR100958139B1 (ko) * 2008-03-31 2010-05-18 주식회사 인트론바이오테크놀로지 엔테로코쿠스 패칼리스 특이적 사멸능을 갖는 신규한박테리오파지
PL215522B1 (pl) 2008-09-29 2013-12-31 Inst Immunologii I Terapii Doswiadczalnej Pan Nowe szczepy bakteriofagów do leczenia zakazen bakteryjnych, zwlaszcza szczepami bakterii lekoopornych rodzaju Enterococcus
KR100988771B1 (ko) * 2008-09-29 2010-10-20 주식회사 인트론바이오테크놀로지 엔테로코쿠스 및 스트렙토코쿠스 특이적 사멸능을 갖는 신규한 리신 단백질
RU2580248C9 (ru) * 2009-02-06 2018-01-17 Текнофахе, Инвестигасао Э Десенвольвименто Эм Биотекнолохия, Са Бактериофаг, обладащий активностью против pseudomonas aeruginosa, белки бактериофага и способы их применения
WO2017177196A1 (fr) 2016-04-08 2017-10-12 The Trustees Of Princeton University Nouvelles compositions antimicrobiennes et méthodes d'utilisation
KR101957266B1 (ko) * 2017-02-22 2019-03-13 주식회사 인트론바이오테크놀로지 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
KR101822812B1 (ko) * 2017-02-22 2018-01-29 주식회사 인트론바이오테크놀로지 신규한 엔테로코쿠스 패슘 박테리오파지 Ent-FAP-4 및 이의 엔테로코쿠스 패슘 증식 억제 용도
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
KR102203679B1 (ko) * 2018-12-26 2021-01-15 주식회사 옵티팜 신규한 엔테로코커스 패시움 균 특이 박테리오파지 ef44 및 이를 포함하는 항균 조성물
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
IL309276A (en) * 2021-06-15 2024-02-01 Ferring Bv Bacteriophages against vancomycin-resistant enterococci
WO2024003301A1 (fr) 2022-06-29 2024-01-04 Snipr Biome Aps Ciblage de cellules d'e. coli

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699322B2 (en) * 1994-04-05 1998-12-03 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage

Also Published As

Publication number Publication date
JP2002543816A (ja) 2002-12-24
AU4971900A (en) 2000-12-05
WO2000069269A1 (fr) 2000-11-23
WO2000069269A9 (fr) 2002-02-21
EP1180937A4 (fr) 2004-08-04
EP1180937A1 (fr) 2002-02-27

Similar Documents

Publication Publication Date Title
CA2373486A1 (fr) Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine
Alisky et al. Bacteriophages show promise as antimicrobial agents
US6121036A (en) Compositions containing bacteriophages and methods of using bacteriophages to treat infections
US11492378B2 (en) Antibacterial protein EFAL-2 having bacteriolytic ability with respect to Enterococcus faecium
CN103501809B (zh) 针对肺炎链球菌（Streptococcus Pneumoniae）的疫苗和组合物
JP7449967B2 (ja) 療法バクテリオファージ組成物
CN112218659A (zh) 用于治疗葡萄球菌感染的治疗性噬菌体组合物
US20010043924A1 (en) Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system
Dhungana et al. Therapeutic efficacy of bacteriophage therapy to treat carbapenem resistant Klebsiella pneumoniae in mouse model
EP3569701A1 (fr) Nouveaux bactériophages
AU2004200450B2 (en) Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium
Gentry Roxithromycin, a new macrolide antibiotic, in the treatment of infections in the lower respiratory tract: an overview
WO2004020635A1 (fr) Bacteriophages et remedes pour une infection bacterienne
WO2019211635A1 (fr) Composition antimicrobienne et son utilisation
US20040146490A1 (en) Antibacterial therapy for multi-drug resistant bacteria
Debattista Phage therapy: where East meets West
US20230416694A1 (en) Modified bacteriophage
EP3442551A1 (fr) Souche de bactériophage capable de produire une infection lytique dans le clone st131-025b:h4 d'escherichia coli
Jacobs et al. Streptococcus pneumoniae: activity of newer agents against penicillin-resistant strains
Kaplan The emerging antibiotic resistance of Streptococcus pneumoniae
Sahni Review on Phage Therapy
Wang Dawn of antimicrobials: Using phages to synergize with antibiotics to counteract bacteria
Godány et al. Phage therapy: Alternative approach to antibiotics

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead